Press coverage about Isotechnika Pharma (NASDAQ:AUPH) (TSE:AUP) has been trending somewhat positive on Friday, according to Accern. The research group scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Isotechnika Pharma earned a news impact score of 0.25 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 46.0328293948756 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Seaport Global Securities Comments on Isotechnika Pharma Inc.’s FY2018 Earnings (AUPH) (americanbankingnews.com)
- Isotechnika Pharma Inc. (AUPH) Given Consensus Rating of “Buy” by Brokerages (americanbankingnews.com)
- Isotechnika Pharma Inc. (AUPH) Expected to Post Quarterly Sales of $50,000.00 (americanbankingnews.com)
- Isotechnika Pharma (AUPH) Upgraded to “Hold” by BidaskClub (americanbankingnews.com)
- Isotechnika Pharma (AUPH) Receives Buy Rating from Cantor Fitzgerald (americanbankingnews.com)
Isotechnika Pharma stock opened at $6.11 on Friday. The firm has a market cap of $527.84 million, a price-to-earnings ratio of -6.64 and a beta of 2.26. Isotechnika Pharma has a fifty-two week low of $6.28 and a fifty-two week high of $6.64.
Isotechnika Pharma (NASDAQ:AUPH) (TSE:AUP) last released its quarterly earnings results on Thursday, May 10th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.02). The company had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $0.05 million. Isotechnika Pharma had a negative return on equity of 20.67% and a negative net margin of 8,193.08%. sell-side analysts forecast that Isotechnika Pharma will post -0.69 EPS for the current fiscal year.
Several research firms recently weighed in on AUPH. Zacks Investment Research raised Isotechnika Pharma from a “sell” rating to a “hold” rating in a research note on Monday, February 12th. ValuEngine raised Isotechnika Pharma from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. BidaskClub raised Isotechnika Pharma from a “sell” rating to a “hold” rating in a research note on Wednesday. Seaport Global Securities reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Isotechnika Pharma in a research note on Friday, March 16th. Finally, Cantor Fitzgerald set a $16.00 price objective on Isotechnika Pharma and gave the company a “buy” rating in a research note on Wednesday. One analyst has rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Isotechnika Pharma presently has a consensus rating of “Buy” and a consensus target price of $10.92.
Isotechnika Pharma Company Profile
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the development of a therapeutic drug to treat autoimmune diseases in Canada and internationally. The company is developing Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It has partnership agreements with Paladin Labs Inc and 3SBio, Inc The company was formerly known as Isotechnika Pharma Inc and changed its name to Aurinia Pharmaceuticals Inc in October 2013.
Receive News & Ratings for Isotechnika Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Isotechnika Pharma and related companies with MarketBeat.com's FREE daily email newsletter.